Stilla raises €20m in series B financing roundFrench Stilla Technologies SA raised €20m in a Series B funding to boost digital PCR-based genetic testing. more ➔
BIH scientists optimise CRISPR gene scissorsTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects". more ➔
Azafaros BV raises €25m in Series A roundDutch biotech Azafaros B.V. has closed a €25m Series A financing round. more ➔
Researchers identify roots of childhood asthma Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children. more ➔
MaaT Pharma raise €18m to advance clinical pipeline MaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline. more ➔
Valneva raises US$85mFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme. more ➔
EMA greenlights 15 new medsThe EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting. more ➔
Sleeping sickness target deciphered Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness. more ➔
UK researchers present dengue virus transmission mapScientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates. more ➔
AMR: IMI’s Enable project reaches endpointsThe ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development. more ➔
